RESUMEN
There were analyzed 23 cases with non-tuberculosis mycobacterium infection, including 19 with mycobacteriosis and 4 with symptoms of colonisation. Among them nine patients were treated less than 6 months, but 14 ones were treated with different antituberculotic schedules during 6-24 months. In 9 patients of this group a sputum negativity was achieved. On the other hand, recurrents of mycobacteriosis was determined in 3 patients. Total observation period was extended from 2 to 6 years.
Asunto(s)
Infecciones por Mycobacterium no Tuberculosas/microbiología , Infecciones del Sistema Respiratorio/microbiología , Tuberculosis Pulmonar/microbiología , Adulto , Anciano , Anciano de 80 o más Años , Farmacorresistencia Microbiana , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Infecciones por Mycobacterium no Tuberculosas/tratamiento farmacológico , Micobacterias no Tuberculosas/efectos de los fármacos , Micobacterias no Tuberculosas/aislamiento & purificación , Neumonía Bacteriana/tratamiento farmacológico , Neumonía Bacteriana/microbiología , Recurrencia , Infecciones del Sistema Respiratorio/tratamiento farmacológico , Esputo/microbiología , Resultado del Tratamiento , Tuberculosis Pulmonar/tratamiento farmacológicoAsunto(s)
Antituberculosos/uso terapéutico , Tuberculosis/tratamiento farmacológico , Animales , Antituberculosos/farmacología , Antituberculosos/toxicidad , Ciprofloxacina/farmacología , Ciprofloxacina/uso terapéutico , Ciprofloxacina/toxicidad , Clofazimina/farmacología , Clofazimina/uso terapéutico , Clofazimina/toxicidad , Evaluación de Medicamentos , Evaluación Preclínica de Medicamentos , Humanos , Técnicas In Vitro , Ratones , Mycobacterium tuberculosis/efectos de los fármacos , Ofloxacino/farmacología , Ofloxacino/uso terapéutico , Ofloxacino/toxicidad , Rifabutina , Rifamicinas/farmacología , Rifamicinas/uso terapéutico , Rifamicinas/toxicidad , Tuberculosis/microbiologíaRESUMEN
Two cases of chronic, cavernous pulmonary tuberculosis with bacilli resistant to several drugs are presented. Both patients were treated with a new antituberculous drug ofloxacin. The agent was used with other antituberculous drugs. Sputum negativization was seen in only one of the patients, while the in other only a decrease of dissemination was observed.
Asunto(s)
Antituberculosos/uso terapéutico , Mycobacterium tuberculosis/efectos de los fármacos , Ofloxacino/uso terapéutico , Tuberculosis Pulmonar/tratamiento farmacológico , Adulto , Enfermedad Crónica , Ensayos Clínicos como Asunto , Farmacorresistencia Microbiana , Femenino , Humanos , Masculino , Persona de Mediana Edad , Tuberculosis Pulmonar/microbiologíaRESUMEN
The aim of the study was to determine the therapeutical effectiveness of a new regimen in freshly diagnosed cases of pulmonary tuberculosis. In this model PZA and SM were excluded, but INH administration was prolonged. Instead of INH and RMP a combined drug was given--RIFAMAZIDE (Polfa). Therapy was carried out in three stages: I stage lasting 3 months during which Rifamazide (600 mg RMP, 300 mg INH) and EMB (25 mg per kg b.w.) was given; II stage-during which Rifamazide was given (2 tablets.) for 3 months; III stage--INH monotherapy (300 mg daily) was continued for 6 months. During the first stage all patients were hospitalized at the Institute of Tuberculosis. The second stage was carried out under supervision of an out-patient clinic. During the third stage patients received their INH at their homes. The study group consisted initially of 58 patients, of which 11 were dropped out due to primary resistance, change of therapy, non-compliance, and non-tolerance of drugs. The final evaluation was carried out basing on results from 47 patients. In all patients a negative sputum culture was achieved. In most during the first two months of therapy. All demonstrated improvement in radiological evaluation. In 38 patients the follow-up lasted 2-6 years, in the remaining nine 2 years. Recurrencies were not observed. Good acceptation by the patients of Rifamazide was found.